RxDoctor Payments Data

Stanley Hatesohl, MD

Family Medicine · Hot Springs Village, ARNPI 1396793741

Payments from drug & device makers

$1,759in general payments, 2019–2025

Across 52 payments — averaging $33.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$875
  • Amgen$148
  • Lilly USA, LLC$124
  • Novo Nordisk$115
  • Helsinn Therapeutics (U.S.), Inc.$78
  • Aclaris Therapeutics, Inc.$76
  • plus $344 from 12 others

What the payments were for

  • Food & beverage$1,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,759 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$186,166
Medicare patients
797
Services billed
8,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$130,344
EliquisApixaban91$93,357
MounjaroTirzepatide62$72,436
XareltoRivaroxaban48$53,783
TrulicityDulaglutide28$46,017
JardianceEmpagliflozin34$37,785
MyrbetriqMirabegron42$37,288
FarxigaDapagliflozin Propanediol33$36,178
Repatha SureclickEvolocumab23$18,505
JanuviaSitagliptin Phosphate16$14,914
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$11,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,036
Tresiba Flextouch U-200Insulin Degludec11$10,618
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,920
Atorvastatin Calcium731$6,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$115$130,34477 claims
Lilly USA, LLCMounjaro, Trulicity$124$118,45390 claims
PfizerEliquis$32$93,35791 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$875$51,03064 claims
GSKAnoro Ellipta, Trelegy Ellipta, Arexvy$39$27,42155 claims
AbbVieSynthroid$48$3,44462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Hot Springs Village

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →